1Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma [ J] Leukemia, 2006,20 (9) : 1467-1473.
2Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials : report of the International Myeloma Workshop Consensus Panel 1 [ J ]. Blood ,2011, 117 ( 18 ) : 4691 4695.
3Palumbo A, Rajkumar SV, San Miguel JF, et al. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation [ J ]. J C1in Oncol, 2014,32(6) : 587-600.
5Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma [ J]. Blood,2015,125 (20) : 3059-3068.
6Mailankody S, Korde N, Lesokhin AM, et al. Minimal residual disease in multiple myeloma: bringing the bench to the bedside [J]. Nat Rev Clin 0ncol,2015,12(5) : 286-295.
7Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma [ J]. Blood,2014,123 (20) : 3073-3079.
8Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologons transplantation [ J ]. Blood, 2011, 118(23) : 5989-5995.
9Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma [ J ]. Br J Haematol, 2012,159 (5) : 499-513.
1Cea M,Cagnetta A,Gobbi M,et al.New insights into the treatment of multiple myeloma with histone deacetylase inhibitors[J].Curr Pharm Des,2013,19(4):734-744.
